Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from AbbVie ( (ABBV) ).
On February 24, 2026, AbbVie entered into an underwriting agreement with a syndicate of major banks to issue a total of $7.5 billion in senior notes across multiple tranches maturing between 2028 and 2066, including floating rate and fixed-rate instruments. The notes were priced at or just below par and registered under AbbVie’s existing shelf registration, with the offering expected to close on March 4, 2026, subject to customary conditions.
AbbVie expects to receive approximately $7.95 billion in net proceeds from the offering, which it intends to use to repay amounts outstanding under a $4.0 billion 364-day delayed draw term loan facility maturing in May 2026 and for general corporate purposes, including potential repayment or repurchase of other debt. The transaction underscores AbbVie’s continued use of the bond market to manage its capital structure, extend its debt maturities and maintain financial flexibility, while underwriters and their affiliates may continue to provide various financial and banking services to the company.
The most recent analyst rating on (ABBV) stock is a Hold with a $230.00 price target. To see the full list of analyst forecasts on AbbVie stock, see the ABBV Stock Forecast page.
Spark’s Take on ABBV Stock
According to Spark, TipRanks’ AI Analyst, ABBV is a Neutral.
The score is primarily held back by balance-sheet risk (high leverage/negative equity) and an expensive P/E multiple despite solid cash generation. Offsetting these are constructive technicals and a notably positive earnings outlook with strong 2026 guidance driven by continued strength in key growth franchises.
To see Spark’s full report on ABBV stock, click here.
More about AbbVie
AbbVie Inc., a global biopharmaceutical company, develops and markets prescription drugs across immunology, oncology, neuroscience and other specialty therapeutic areas. The company focuses on innovative medicines and maintains an active presence in global capital markets to support its research, development and strategic corporate needs.
Average Trading Volume: 6,418,770
Technical Sentiment Signal: Buy
Current Market Cap: $403.9B
See more data about ABBV stock on TipRanks’ Stock Analysis page.